Norgestomet

Norgestomet

SCHEMBL140381

CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4[C@H]3[C@@H](C)C[C@@]21C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 7/20 1.00
▸ CYP3A4 P08684 6/20 0.54
▸ AR P10275 6/20 0.54
▸ NR3C1 P04150 5/20 0.54
▸ LMNA P02545 5/20 0.54
▸ SMN1; SMN2 Q16637 4/20 0.54
▸ ABCB11 O95342 3/20 0.54
▸ CHRM2 P08172 3/20 0.54
▸ CHRM1 P11229 3/20 0.54
▸ NPSR1 Q6W5P4 3/20 0.54
▸ ESR1 P03372 2/20 0.54
▸ ALDH1A1 P00352 2/20 0.54
▸ USP2 O75604 2/20 0.54
▸ ABCC4 O15439 1/20 0.54
▸ SHBG P04278 1/20 0.54
▸ NR3C2 P08235 1/20 0.54
▸ HRH2 P25021 1/20 0.54
▸ AKR1C3 P42330 1/20 0.54
▸ AKR1C2 P52895 1/20 0.54
▸ AKR1C1 Q04828 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Norgestomet SCHEMBL140382 1.00 PGR (1.00) PGRCYP3A4ARNR3C1LMNA
Norgestomet SCHEMBL11794624 1.00 PGR (1.00) PGRCYP3A4ARNR3C1LMNA
SCHEMBL6842375 0.85 PGR (0.75) PGRCYP3A4ARNR3C1LMNA
SCHEMBL8507942 0.85 PGR (0.73) PGRCYP3A4ARNR3C1LMNA
SCHEMBL25334510 0.84 PGR (0.72) PGRCYP3A4ARNR3C1LMNA
SCHEMBL10954178 0.84 PGR (0.72) PGRCYP3A4ARNR3C1LMNA
SCHEMBL22400061 0.84 PGR (0.72) PGRCYP3A4ARNR3C1LMNA
SCHEMBL10951986 0.84 PGR (0.72) PGRCYP3A4ARNR3C1LMNA
SCHEMBL29403102 0.84 PGR (0.72) PGRCYP3A4ARNR3C1LMNA
SCHEMBL8769149 0.77 PGR (0.63) PGRCYP3A4ARNR3C1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4419179-A1 BREATH-POWERED NASAL DEVICES FOR TREATMENT OF TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSION, AND METHODS AND METHODS Oragenics, Inc. (US) 2024-08-28 — — EP claimed
WO-2023069126-A1 BREATH-POWERED NASAL DEVICES FOR TREATMENT OF TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSION, AND METHODS AND METHODS ODYSSEY HEALTH, INC. (US) 2023-04-27 — — WO claimed
US-20200376002-A1 Injectable Hormone Formulations for Estrous Cycle Control in Mammals, its Manufacturing Process, Estrous Cycle Control and Puberty Triggering Methods, and Pregnancy Enhancement in Mammals Applied Technologies Consultants Inc. (US) 2020-12-03 — — US claimed
US-20200368221-A1 SOLID PARTICLE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SOLID PARTICLE SHANGHAI WD PHARMACEUTICAL CO., LTD (CN) 2020-11-26 — — US claimed
EP-3738582-A1 SOLID PARTICLE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SOLID PARTICLE Shanghai WD Pharmaceutical Co., Ltd (CN) 2020-11-18 — — EP claimed
CN-111565712-A Solid particle, preparation method thereof and pharmaceutical composition containing solid particle 上海汉都医药科技有限公司 2020-08-21 — — CN claimed
CN-110013467-A A kind of solia particle and preparation method thereof and pharmaceutical composition containing it 上海汉都医药科技有限公司 2019-07-16 — — CN claimed
EP-3501543-A1 METHOD FOR MANUFACTURING VAGINAL DRUG DELIVERY SYSTEMS USING A THREE DIMENSIONAL PRINTER Delim Cosmetics & Pharma S.r.l. (IT) 2019-06-26 — — EP claimed
CN-109575098-A The synthetic method of norgestomet 湖南成大生物科技有限公司 2019-04-05 — — CN claimed
US-9763962-B2 Estrus synchronization preparations and effective CIDR-less protocols YOAKUM JENNIFER (US) 2017-09-19 — — US claimed
EP-0422100-A4 — — 1994-04-27 — — EP claimed
US-5141748-A Rods shaped crosslinked polysiloxane copolymer matrix HOFFMANN-LA ROCHE, INC. (US) 1992-08-25 — — US claimed
EP-0491803-A1 IMPLANTABLE DELIVERY DISPENSER. ALZA CORP (US) 1992-07-01 — — EP claimed
US-5112614-A IMPLANTABLE DELIVERY DISPENSER ALZA CORPORATION (US) 1992-05-12 — — US claimed
US-5073548-A Antiprogestational, progestational and antiglucocorticoid activity; glandular disorders; vision defects; antifertility agents RESEARCH TRIANGLE INSTITUTE (US) 1991-12-17 — — US claimed
EP-0422100-A1 11-g(b)-SUBSTITUTED PROGESTERONE ANALOGS. RES TRIANGLE INST (US) 1991-04-17 — — EP claimed
WO-1991004016-A1 IMPLANTABLE DELIVERY DISPENSER ALZA CORPORATION (US) 1991-04-04 — — WO claimed
US-4954490-A HORMONE INHIBITORS RESEARCH TRIANGLE INSTITUTE (US) 1990-09-04 — — US claimed
WO-1989012448-A1 11beta-SUBSTITUTED PROGESTERONE ANALOGS RESEARCH TRIANGLE INSTITUTE (US) 1989-12-28 — — WO claimed
US-4472394-A Method for increasing weight in domestic animals G. D. SEARLE & CO. (US) 1984-09-18 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200368221-A1 SOLID PARTICLE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SOLID PARTICLE MGLL, FAR1, NOTUM PGR 1015/4885CYP3A4 559/4885AR 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback